BSEAptus Pharma LtdMediumNeutral
Announced Thu, 14 May · 08:35 IST

The Exchange has received the disclosure under Regulation 29(1) / 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Milly Chetan Lalseta

Promoter Stake BuyOwnership Changes View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.4%1-day move
₹185.80
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.4-1.8-0.4-0.4-2.0-3.4+23.6+14.0+32.9
Up moveDown movePending
AI summary

Promoter Milly Chetan Lalseta acquired 18,000 equity shares of Aptus Pharma Limited on May 11, 2026 through an inter-se transfer within the promoter group. Before the acquisition, she held 5,75,000 shares (8.38% of total capital). After the acquisition, her holding increased to 5,93,000 shares representing 8.64% of the company's total voting capital of 68,60,000 equity shares. The company is listed on BSE's SME platform with scrip code 544529. This is a routine promoter-to-promoter share transfer that increases the acquiring promoter's stake in the company.

Likely market impact

This is a routine intra-promoter group transaction and has neutral impact on the stock. It does not change the total promoter group holding and is unlikely to affect share price or minority shareholder interests.